- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01617499
Physical Activity for Campus Employees (PACE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cardiovascular disease (CVD) persists as the leading cause of mortality in the United States and accounts for 17 percent of the nation's overall health expenditures. Although the mortality rate of CVD has declined in recent years, the burden of disease remains high. Currently, 1 in 3 Americans has some form of CVD. Additionally, according to a recent policy statement published by the American Heart Association (AHA), 40% of the population is projected to have some form of CVD by 2030. Furthermore, the AHA has projected that the cost to treat CVD will triple by 2030. The prevalence and rising financial burden of CVD demonstrate the urgency for effective implementation of disease prevention strategies.
Evidence suggesting the majority of CVD is preventable through modifiable risk factor management continues to grow. Nonetheless, difficulty controlling modifiable risk factors remains an issue for many Americans. The magnitude of this challenge is supported by a study revealing that 78% of adults are candidates for at least one CVD prevention activity. Although national organizations have published a variety of disease prevention recommendations, widespread implementation of and adherence to preventative programs remain problematic. Consequently, a large proportion of the population is not receiving or participating in prevention strategies from which they may benefit. The full potential of reducing the nation's CVD burden cannot be achieved unless interventions are implemented on a larger scale, with reduced costs, and with increased initial and continued participation.
With approximately 130 million Americans currently employed, workplaces provide ideal environments for implementation of sizable, cost-effective CVD prevention programs. However, successful wellness programming remains a laborious, resource intensive challenge for employers. In 2004, a National Worksite Health Promotion Survey disclosed that less than 7% of U.S. employers offered worksite wellness programs. Furthermore, an estimated 25-30% of companies' annual medical costs are spent on employees with CVD risk factors.
In the proposed study, a worksite wellness program that includes health assessments, personal health reports, and pedometer-based tracking of physical activity will be offered to university employees. Participants will not be randomized to an intervention or control group. Rather, program components will be available to all enrolled participants, and each individual may choose whether to wear a pedometer, track their step counts, attend wellness sessions, and/or complete the health assessments. There is no prescribed intervention. Wellness sessions include educational information on lifestyle behaviors to promote cardiometabolic health.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Missouri
-
St. Louis, Missouri, United States, 63108
- Washington University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- employee of Washington University in St. Louis
Exclusion Criteria:
- pregnancy
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
University employees
Participants will include employees of Washington University in St. Louis.
Recruitment will be directed to staff employees of the Central Fiscal Unit (CFU) on the Danforth campus.
|
The worksite wellness program included cardiovascular health assessments, personal health reports, 8 weeks of pedometer-based walking and tracking activities, and weekly wellness sessions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Daily Step Count (determined by pedometer)
Time Frame: Baseline, week 4, and week 8
|
Daily step counts, as recorded by pedometers, will be self-reported by participants for 7 continuous days at 3 study time points: baseline, week 4, and week 8.
|
Baseline, week 4, and week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body weight
Time Frame: Baseline and week 9
|
Body weight will be measured on a digital scale in the morning after an overnight fast.
Shoes, jewelry, sweaters, jackets, belts, and hats will be removed and pockets will be emptied before the measurement is made.
|
Baseline and week 9
|
Body Mass Index (BMI)
Time Frame: Baseline and week 9
|
BMI will be computed as weight in kilograms divided by height in meters squared.
Weight Status will be determined using standard CDC BMI categories.
|
Baseline and week 9
|
Body Composition
Time Frame: Baseline and week 9
|
Fat mass (kg), fat free mass (kg), and percentage body fat will be determined by bioelectrical impedance analysis using the InBody 520 analyzer.
|
Baseline and week 9
|
waist circumference
Time Frame: Baseline and week 9
|
Waist circumference will be measured at the border of the iliac crest using a Gulick II tape measure.
|
Baseline and week 9
|
Blood Pressure
Time Frame: Baseline and week 9
|
Systolic and diastolic blood pressure will be measured in duplicate in the right arm after 10 minutes of seated rest using the Omron HEM-907XL Professional Digital Blood Pressure Monitors (Omron Healthcare, Kyoto, Japan).
One minute rest will be provided between the 2 measurements.
|
Baseline and week 9
|
Fasting plasma glucose
Time Frame: Baseline and week 9
|
Fasting plasma glucose will be measured from a fingerstick blood sample in the morning after an overnight fast using the Cholestech LDX System® (Hayward, CA).
|
Baseline and week 9
|
Total Cholesterol
Time Frame: Baseline and week 9
|
Total cholesterol will be quantified from a fingerstick blood sample in the morning after an overnight fast using the Cholestech LDX System® (Hayward, CA).
|
Baseline and week 9
|
LDL Cholesterol
Time Frame: Baseline and week 9
|
LDL cholesterol will be computed using the Friedewald equation from the lipid profile measured from a fingerstick blood sample in the morning after an overnight fast using the Cholestech LDX System® (Hayward, CA).
|
Baseline and week 9
|
HDL Cholesterol
Time Frame: Baseline and week 9
|
HDL cholesterol will be quantified from a fingerstick blood sample in the morning after an overnight fast using the Cholestech LDX System® (Hayward, CA).
|
Baseline and week 9
|
Triglycerides
Time Frame: Baseline and week 9
|
Triglycerides will be quantified from a fingerstick blood sample in the morning after an overnight fast using the Cholestech LDX System® (Hayward, CA).
|
Baseline and week 9
|
Non-HDL Cholesterol
Time Frame: Baseline and week 9
|
Non-HDL cholesterol will be computed by difference based on the lipid profile determined from a fasted fingerstick blood sample using the Cholestech LDX System® (Hayward, CA).
|
Baseline and week 9
|
Resting heart rate
Time Frame: Baseline and week 9
|
Resting heart rate will be measured in duplicate in the morning after 10 minutes of seated rest using Omron HEM-907XL Professional Digital Blood Pressure Monitors (Omron Healthcare, Kyoto, Japan).
|
Baseline and week 9
|
Cardiorespiratory fitness based on post-exercise recovery heart rate
Time Frame: Baseline and week 9
|
Cardiorespiratory fitness will be estimated based on heart rate recovery following a 3-minute step test performed with an 8-inch step and a metronome set to 96 beats/minute.
Participants will be instructed to maintain the pace set by the beat of the metronome for 3 consecutive minutes and to be seated immediately at the completion of the 3-minute test.
The subject's right radial pulse rate will be measured for 30 seconds, beginning 30 seconds after the completion of the test.
Cardiorespiratory fitness level will be computed based on sex- and age-specific heart rate criteria.
|
Baseline and week 9
|
Dietary patterns
Time Frame: Baseline and week 9
|
Dietary patterns will be assessed using the nutrition questions from the CDC Behavioral Risk Factor Surveillance System (BRFSS).
|
Baseline and week 9
|
Physical activity patterns
Time Frame: Baseline and week 9
|
Physical activity patterns will be assessed using the exercise questions from the CDC Behavioral Risk Factor Surveillance System (BRFSS).
|
Baseline and week 9
|
Perceived barriers to exercise participation
Time Frame: Baseline and week 9
|
Perceived barriers to exercise participation will be assessed using the "Exercise Barriers" questionnaire, which the subject will complete on his/her own.
|
Baseline and week 9
|
Perceived benefits of exercise
Time Frame: Baseline and week 9
|
Perceived benefits of exercise will be assessed using the "Exercise Benefits" questionnaire, which the subject will complete on his/her own.
|
Baseline and week 9
|
Participant evaluation of the wellness program
Time Frame: Weeks 12 - 14
|
Participants will be asked to provide feedback about the wellness program through a 10-question, anonymous, online survey administered using the web-based Survey Monkey tool.
|
Weeks 12 - 14
|
Collaborators and Investigators
Investigators
- Principal Investigator: Susan B Racette, PhD, Washington University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201109022
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
Morehouse School of MedicineNot yet recruiting
-
Yonsei UniversityRecruitingCardiovascular DiseaseKorea, Republic of
-
Nanjing Medical UniversityNot yet recruitingCardiovascular Disease
-
National Human Genome Research Institute (NHGRI)Active, not recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
AmgenCompletedCardiovascular DiseaseUnited States, Australia
-
VA Office of Research and DevelopmentEnrolling by invitationCardiovascular DiseaseUnited States
Clinical Trials on Physical activity
-
Health Education Research Foundation (HERF)CompletedQuality of LifePakistan
-
Zohra Institute of Health SciencesCompletedPhysical Activity and StressPakistan
-
Centre Hospitalier Universitaire DijonWithdrawn
-
Fundacion para la Investigacion y Formacion en...CompletedImpaired CognitionSpain
-
Cardenal Herrera UniversityRecruiting
-
Istituti Clinici Scientifici Maugeri SpAActive, not recruiting
-
AUSL Romagna RiminiFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRecruitingNon-Small Cell Lung CancerItaly
-
Fundación para la Investigación del Hospital Clínico...CompletedObesity | Severe Mental Disorder
-
Augusta UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Kansas... and other collaboratorsCompletedMental Disorders, SevereUnited States
-
Centre Hospitalier Departemental VendeeTerminated